ADAM33 as a New Biomarker for Invasive Lobular Breast Carcinoma

Invasive ductal carcinoma (IDC) and invasive lobular breast carcinoma (ILC) are the most common malignancies compromising the breast tissue in women worldwide. ILCs tend to form metastasisin remote locations, such as the gastrointestinal tract, peritoneal surface and retroperitoneum, compared with IDCs that move preferentially to the lymph nodes, lung, pleura, liver, brain and bones. The histological characteristics of these two tumors are very similar and there is no useful molecular marker to differentiate IDC from ILC to date. In this study, we cloned and expressed ADAM33 recombinant protein cystein rich domain in order to produce polyclonal antibodies and used it as a new immnunohistochemical molecular biomarker that specifically recognizes the ILC breast cancer subtype.